home
portfolio
approach
team
careers
news
contact
investor portal
home
portfolio
approach
team
careers
news
contact
investor portal
Nextech Invest
Blueprint Medicines Debuts Preclinical Data for First-in-Class RET Drug Candidate
Blueprint Medicines Debuts Preclinical Data for First-in-Class RET Drug Candidate
Post navigation
Previous Post
Previous
MacroGenics Presents Updated Data from Phase 1 Study of Margetuximab at ASCO Annual Meeting 2015
Next Post
Next
Blueprint Medicines Receives FDA Authorization to Proceed with Clinical Trials for Two Drug Candidates